BIOMARIN PHARMACEUTICAL INC Sales Revenue, Goods, Net (Deprecated 2018-01-31)
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $369.10 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-04-27
- BIOMARIN PHARMACEUTICAL INC sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $369.10M, a 22.14% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $353.58M, a 18.58% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $298.75M, a 7.36% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $315.93M, a 5.81% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $1.27B, a 14.42% increase from fiscal 2016.
- BIOMARIN PHARMACEUTICAL INC sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $1.11B, a 25.53% increase from fiscal 2015.
- BIOMARIN PHARMACEUTICAL INC sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $884.52M, a 19.79% increase from fiscal 2014.
- BIOMARIN PHARMACEUTICAL INC sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $738.42M, a 37.16% increase from fiscal 2013.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $369.10M 10-Q · filed 2018-04-27 | $722.68M derived: sum of 2 quarters · filed 2018-04-27 | $1.02B derived: sum of 3 quarters · filed 2018-04-27 | $1.34B derived: sum of 4 quarters · filed 2018-04-27 |
| 2017-12-31 | $353.58M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $652.33M derived: sum of 2 quarters · filed 2018-02-26 | $968.25M derived: sum of 3 quarters · filed 2018-02-26 | $1.27B 10-K · filed 2018-02-26 |
| 2017-09-30 | $298.75M 10-Q · filed 2017-10-31 | $614.68M derived: sum of 2 quarters · filed 2017-10-31 | $916.87M 10-Q · filed 2017-10-31 | $1.22B derived: sum of 4 quarters · filed 2018-04-27 |
| 2017-06-30 | $315.93M 10-Q · filed 2017-08-02 | $618.12M 10-Q · filed 2017-08-02 | $916.30M derived: sum of 3 quarters · filed 2018-04-27 | $1.19B derived: sum of 4 quarters · filed 2018-04-27 |
| 2017-03-31 | $302.19M 10-Q · filed 2018-04-27 | $600.38M derived: sum of 2 quarters · filed 2018-04-27 | $878.64M derived: sum of 3 quarters · filed 2018-04-27 | $1.18B derived: sum of 4 quarters · filed 2018-04-27 |
| 2016-12-31 | $298.19M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $576.45M derived: sum of 2 quarters · filed 2018-02-26 | $875.02M derived: sum of 3 quarters · filed 2018-02-26 | $1.11B 10-K · filed 2018-02-26 |
| 2016-09-30 | $278.26M 10-Q · filed 2017-10-31 | $576.84M derived: sum of 2 quarters · filed 2017-10-31 | $812.20M 10-Q · filed 2017-10-31 | $1.04B derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-06-30 | $298.58M 10-Q · filed 2017-08-02 | $533.93M 10-Q · filed 2017-08-02 | $760.35M derived: sum of 3 quarters · filed 2018-02-26 | $968.12M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-03-31 | $235.36M 10-Q · filed 2017-05-04 | $461.78M derived: sum of 2 quarters · filed 2018-02-26 | $669.54M derived: sum of 3 quarters · filed 2018-02-26 | $918.57M derived: sum of 4 quarters · filed 2018-02-26 |
| 2015-12-31 | $226.42M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $434.19M derived: sum of 2 quarters · filed 2018-02-26 | $683.21M derived: sum of 3 quarters · filed 2018-02-26 | $884.52M 10-K · filed 2018-02-26 |
| 2015-09-30 | $207.77M 10-Q · filed 2016-11-03 | $456.79M derived: sum of 2 quarters · filed 2016-11-03 | $658.10M 10-Q · filed 2016-11-03 | $885.85M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-06-30 | $249.02M 10-Q · filed 2016-08-08 | $450.33M 10-Q · filed 2016-08-08 | $678.09M derived: sum of 3 quarters · filed 2017-02-27 | $851.50M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-03-31 | $201.31M 10-Q · filed 2016-05-02 | $429.06M derived: sum of 2 quarters · filed 2017-02-27 | $602.48M derived: sum of 3 quarters · filed 2017-02-27 | $790.72M derived: sum of 4 quarters · filed 2017-02-27 |
| 2014-12-31 | $227.75M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $401.17M derived: sum of 2 quarters · filed 2017-02-27 | $589.41M derived: sum of 3 quarters · filed 2017-02-27 | $738.42M 10-K · filed 2017-02-27 |
| 2014-09-30 | $173.42M 10-Q · filed 2015-11-02 | $361.66M derived: sum of 2 quarters · filed 2015-11-02 | $510.66M 10-Q · filed 2015-11-02 | $654.95M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $188.24M 10-Q · filed 2015-08-05 | $337.25M 10-Q · filed 2015-08-05 | $481.53M derived: sum of 3 quarters · filed 2016-02-29 | $615.86M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $149.00M 10-Q · filed 2015-05-05 | $293.29M derived: sum of 2 quarters · filed 2016-02-29 | $427.62M derived: sum of 3 quarters · filed 2016-02-29 | $560.02M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $144.29M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $278.62M derived: sum of 2 quarters · filed 2016-02-29 | $411.02M derived: sum of 3 quarters · filed 2016-02-29 | $538.36M 10-K · filed 2016-02-29 |
| 2013-09-30 | $134.33M 10-Q · filed 2014-10-28 | $266.73M derived: sum of 2 quarters · filed 2014-10-28 | $394.07M 10-Q · filed 2014-10-28 | $525.03M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-06-30 | $132.40M 10-Q · filed 2014-07-31 | $259.74M 10-Q · filed 2014-07-31 | $390.70M derived: sum of 3 quarters · filed 2015-03-02 | $517.01M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-03-31 | $127.34M 10-Q · filed 2014-05-02 | $258.30M derived: sum of 2 quarters · filed 2015-03-02 | $384.61M derived: sum of 3 quarters · filed 2015-03-02 | $507.60M derived: sum of 4 quarters · filed 2015-03-02 |
| 2012-12-31 | $130.96M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $257.27M derived: sum of 2 quarters · filed 2015-03-02 | $380.26M derived: sum of 3 quarters · filed 2015-03-02 | $496.50M 10-K · filed 2015-03-02 |
| 2012-09-30 | $126.31M 10-Q · filed 2013-10-28 | $249.30M derived: sum of 2 quarters · filed 2013-10-28 | $365.54M 10-Q · filed 2013-10-28 | $471.60M derived: sum of 4 quarters · filed 2014-02-26 |
| 2012-06-30 | $122.99M 10-Q · filed 2013-07-29 | $239.23M 10-Q · filed 2013-07-29 | $345.29M derived: sum of 3 quarters · filed 2014-02-26 | $458.19M derived: sum of 4 quarters · filed 2014-02-26 |
| 2012-03-31 | $116.24M 10-Q · filed 2013-04-29 | $222.30M derived: sum of 2 quarters · filed 2014-02-26 | $335.19M derived: sum of 3 quarters · filed 2014-02-26 | $444.81M derived: sum of 4 quarters · filed 2014-02-26 |
| 2011-12-31 | $106.06M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-26 | $218.96M derived: sum of 2 quarters · filed 2014-02-26 | $328.57M derived: sum of 3 quarters · filed 2014-02-26 | $437.65M 10-K · filed 2014-02-26 |
| 2011-09-30 | $112.89M 10-Q · filed 2012-10-29 | $222.51M derived: sum of 2 quarters · filed 2012-10-29 | $331.58M 10-Q · filed 2012-10-29 | $430.06M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | $109.62M 10-Q · filed 2012-08-02 | $218.69M 10-Q · filed 2012-08-02 | $317.17M derived: sum of 3 quarters · filed 2013-02-26 | $413.73M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-03-31 | $109.08M 10-Q · filed 2012-04-30 | $207.55M derived: sum of 2 quarters · filed 2013-02-26 | $304.11M derived: sum of 3 quarters · filed 2013-02-26 | $394.70M derived: sum of 4 quarters · filed 2013-02-26 |
| 2010-12-31 | $98.48M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $195.04M derived: sum of 2 quarters · filed 2013-02-26 | $285.63M derived: sum of 3 quarters · filed 2013-02-26 | $369.70M 10-K · filed 2013-02-26 |
| 2010-09-30 | $96.56M 10-Q · filed 2011-10-31 | $187.15M derived: sum of 2 quarters · filed 2011-10-31 | $271.22M 10-Q · filed 2011-10-31 | $355.18M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-06-30 | $90.59M 10-Q · filed 2011-08-01 | $174.66M 10-Q · filed 2011-08-01 | $258.62M derived: sum of 3 quarters · filed 2012-02-22 | $337.00M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-03-31 | $84.07M 10-Q · filed 2011-04-29 | $168.03M derived: sum of 2 quarters · filed 2012-02-22 | $246.41M derived: sum of 3 quarters · filed 2012-02-22 | $327.88M derived: sum of 4 quarters · filed 2012-02-22 |
| 2009-12-31 | $83.95M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | $162.34M derived: sum of 2 quarters · filed 2012-02-22 | $243.81M derived: sum of 3 quarters · filed 2012-02-22 | $315.72M 10-K · filed 2012-02-22 |
| 2009-09-30 | $78.38M 10-Q · filed 2010-10-29 | $159.85M derived: sum of 2 quarters · filed 2010-10-29 | $231.77M 10-Q · filed 2010-10-29 | |
| 2009-06-30 | $81.47M 10-Q · filed 2010-08-04 | $153.39M 10-Q · filed 2010-08-04 | ||
| 2008-12-31 | $251.85M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |